Fundraising Fox

PanTher Therapeutics

Austin, US · Founded 2014 · Delaware corporation · 18 employees on LinkedIn · 4 known investors

Find your way into PanTher Therapeutics

1,276 people in our graph share verified history with the PanTher Therapeutics team — schools, employers, funds. One of them is your warm intro.

Ken Chenaultunlockedknows Laura Indolfi · together at Chief (overlapped)

×2knows the team · via Harvard Business School

×4knows the team · via Massachusetts General Hospital Cancer Center

×2knows the team · via Liceo Scientifico

×2knows the team · via MIT

knows the team · via Chief

PanTher develops targeted cancer therapeutics that deliver drugs directly to tumor sites at high concentrations over extended periods, aiming to improve clinical outcomes while reducing side effects. The platform is designed to be applicable across multiple therapeutic types for oncology treatment.

Biotech Healthtech Medical Devices

Founders & leadership

PanTher Therapeutics was founded in 2014 by Laura Indolfi and Elazer Edelman.

LI

Laura Indolfi

Laura Indolfi inChief Executive Officer and Co-FounderLaura Indolfi is Co-Founder and CEO of PanTher Therapeutics, a clinical-stage oncology company developing targeted cancer therapeutics delivered directly to tumor sites. She previously worked as a research associate at the Harvard-MIT Institute for Medical Engineering and Science and attended business school at Harvard and Sloan, with expertise spanning drug delivery, cell therapy, and translational medicine.

EE

Elazer EdelmanCo-founder

Board

DM

D Mackey

D Mackey inBoard directorPartner & Chief Financial Officer at Catalyst Health Ventures

DW

Daniel WildmanBoard director

DZ

Darshana Zaveri

Darshana ZaveriBoard directorFounder & Managing Partner at Catalyst Health Ventures

MP

Maria Palasis

Maria PalasisBoard director

DT

David TingBoard director

Investors · 4

Catalyst Health Ventures✓ verifiedBoston · $1M – $3M

Angel Physicians Fund

Mission BiocapitalSan Francisco · $500K

Walnut Venture AssociatesWellesley

Funding

SEC filings, press & company announcements

$21.4M disclosed across 10 of 11 rounds · 2015–2025

$5.4MSeries AJun 2021 · 2 sources
Source ↗

▶$3MraisedApr 2025 · 26 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Laura IndolfiExecutive Officer, Director
D MackeyDirector
Daniel WildmanDirector
Darshana ZaveriDirector
Maria PalasisDirector

Offering amount: $5M
Amount sold: $3M
First sale: Mar 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$2.7MraisedDec 2023 · 28 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

John EdwardsDirector
Daniel WildmanDirector
Laura IndolfiExecutive Officer, Director
Manish BhandariDirector
Maria PalasisDirector
Darshana ZaveriDirector

Offering amount: $5M
Amount sold: $2.7M
First sale: Nov 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1.3MraisedDec 2022 · 15 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Laura IndolfiExecutive Officer, Director
Maria PalasisDirector
David TingDirector
Darshana ZaveriDirector
Manish BhandariDirector

Offering amount: $2M
Amount sold: $1.3M
First sale: Dec 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1.1MraisedJun 2022 · 17 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

DARSHANA ZAVERIDirector
MARIA PALASISDirector
MANISH BHANDARIDirector
LAURA INDOLFIExecutive Officer, Director
DAVID TINGDirector

Offering amount: $1.2M
Amount sold: $1.1M
First sale: Jun 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$7.3MraisedJun 2021 · 59 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Maria PalasisDirector
Manish BhandariDirector
David TingDirector
Laura IndolfiExecutive Officer, Director
Darshana ZaveriDirector

Offering amount: $7.3M
Amount sold: $7.3M
First sale: May 2020
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$209.5KraisedMay 2020 · 15 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

David TingDirector
Laura IndolfiExecutive Officer, Director
Elazer EdelmanDirector

Offering amount: $209.5K
Amount sold: $209.5K
First sale: Jun 2019
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$268.1KraisedMay 2020 · 6 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Elazer EdelmanDirector
Laura IndolfiExecutive Officer, Director
David TingDirector

Offering amount: $268.1K
Amount sold: $268.1K
First sale: Aug 2018
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$35KraisedNov 2016 · 1 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Elazer EdelmanDirector
David TingDirector
Laura IndolfiExecutive Officer, Director

Offering amount: $500K
Amount sold: $35K
First sale: Oct 2016
Incorporated: Corporation, Delaware, 2014
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

PANTHERx10 shared keywordsPANTHERx is an independent specialty pharmacy focused on rare disease care, dispensing and managing therapies for patients with rare conditions across the US. Licensed in all 50 states, it serves patients, prescribers, and manufacturers through a personalized "Rare Pharmacy" model.

Companies competing with PanTher Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Cambridge Massachusetts based PanTher Therapeutics is raising $7,334,474.00 in New Equity Investment. - intelligence360intelligence360.news · Jun 2021

PanTHer Therapeutics Closes $5.4M in Series A Funding - FinSMEsfinsmes.com · Jun 2021

PanTher Therapeutics Closes Oversubscribed $5.4M Series A Round, Expands Board of Directors, As Company Prepares to Initiate First Clinical Trial of Novel Localized Treatment of Pancreatic Cancerbusinesswire.com · Jun 2021

Frequently asked questions

What does PanTher Therapeutics do?: PanTher develops targeted cancer therapeutics that deliver drugs directly to tumor sites at high concentrations over extended periods, aiming to improve clinical outcomes while reducing side effects. The platform is designed to be applicable across multiple therapeutic types for oncology treatment.
Who founded PanTher Therapeutics?: PanTher Therapeutics was founded by Laura Indolfi, Elazer Edelman in 2014.
Who are PanTher Therapeutics's investors?: PanTher Therapeutics's investors include Catalyst Health Ventures, Angel Physicians Fund, Mission Biocapital, Walnut Venture Associates.
How much funding has PanTher Therapeutics raised?: PanTher Therapeutics has disclosed $21.4M raised across 10 of its 11 known rounds.
Where is PanTher Therapeutics headquartered?: PanTher Therapeutics is headquartered in Austin, US.